Anemia hemolítica secundaria a metildopa

Authors

  • Rafael Pila Pérez Hospital Provincial Clínico Quirúrgico Docente Manuel Ascunce Domenech. Camagüey, Cuba.
  • Rafael Pila Peláez
  • Miguel Paulino Basulto

Abstract

RESUMEN

Fundamento: se presentó el caso de una paciente de sesenta y dos años, hipertensa esencial desde hace veinte años. Después de recibir tratamiento con metildopa, dos gramos diarios durante cuatro meses, presenta anemia hemolítica y trombocitopenia, con prueba de Coombs directa positiva. Se discutieron los mecanismos fisiopatológicos posibles, y se reseñaron las drogas capaces de producir esta enfermedad, así como los mecanismos de acción de la metildopa y los efectos hematológicos adversos.

Downloads

Download data is not yet available.

Downloads

Published

2014-07-31

How to Cite

1.
Pila Pérez R, Pila Peláez R, Paulino Basulto M. Anemia hemolítica secundaria a metildopa. Arch méd Camagüey [Internet]. 2014 Jul. 31 [cited 2025 Sep. 4];13(6). Available from: https://revistaamc.sld.cu/index.php/amc/article/view/2293

Issue

Vol. 13 No. 6 (2009)

Section

Case Reports

License

Copyright: Camagüey Medical Archive Magazine, offers immediately after being indexed in the SciELO Project; Open access to the full text of the articles under the principle of making available and free the research to promote the exchange of global knowledge and contribute to a greater extension, publication, evaluation and extensive use of the articles that can be used without purpose As long as reference is made to the primary source.

Conflicts of interest: authors must declare in a mandatory manner the presence or not of conflicts of interest in relation to the investigation presented.

(Download Statement of potential conflicts of interest)

The Revista Archivo Médico de Camagüey is under a License Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 International (CC BY 4.0).

This license allows others to distribute, to mix, to adjust and to build from its work, even for commercial purposes, as long as it is recognized the authorship of the original creation. This is the most helpful license offered. Recommended for maximum dissemination and use of licensed materials. The full license can be found at: https://creativecommons.org/licenses/